Switching from <scp>FOLFIRI</scp> plus cetuximab to <scp>FOLFIRI</scp> plus bevacizumab based on early tumor shrinkage in <scp><i>RAS</i></scp> wild‐type metastatic colorectal cancer: A phase <scp>II</scp> trial (<scp>HYBRID</scp>)
Cancer medicine